Endo sues FDA to block generic Opana; Sandoz to shutter Mumbai facility, cut 150 jobs;

@FiercePharma: ICYMI: Pfizer is cutting its US primary care sales force. $$ down in that group post-Lipitor--Dow Jones. News | Follow @FiercePharma

> Endo Health Solutions ($ENDP) sued the FDA over generic versions of its pain drug Opana ER, which don't employ the crush-resistant technology Endo added to its version to thwart abuse. Report

> Sandoz, the generics unit of Novartis ($NVS), plans to shut down its finished medicine development center in Mumbai, India, and either redeploy or lay off its 150 workers. Report

> South Africa's Aspen Pharmacare wrapped up its buyout of GlaxoSmithKline ($GSK) medicines for £163.8 million, or $263 million. Report

> Novo Nordisk's ($NVO) Ryzodeg insulin cleared its first advisory committee review in Japan; the company expects a marketing clearance within a few months. Report

> Merck KGaA aims to expand in Indonesia, particularly in sales of biotech products under the Merck Millipore brand, an executive said. Report

> Nestle wrapped up its $11.85 billion acquisition of Pfizer's ($PFE) nutrition business. Report

Medical Device News

 @FierceMedDev: NanoString draws $15.3M Series E for cancer diagnostics test launch. Story | Follow @FierceMedDev

@MarkHFierce: SCOTUS will consider whether human genes can be patented. The case has profound implications for the future of Dx. More | Follow @MarkHFierce

 @DamianFierce: A European nonprofit says Big Pharma needs to keep a closer eye on its CRO partners, and ACRO cries foul. Story | Follow @DamianFierce

> Medtronic snags CE mark for critical-care glucose monitor. Report

> FDA to mull reclassification for some circulatory system devices. Item

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: Database aims to speed discoveries for blood cancer treatments. Report | Follow @FierceBiotech

 @JohnCFierce: Another figure for "average" drug R&D costs--1.2B sterling--biotech efficient source of new drugs, via FT. More (sub. req.) | Follow @JohnCFierce

 @RyanMFierce: Say what? Reuters is making some noise about the neglected $4.6B market for hearing-loss drugs. Story | Follow @RyanMFierce

> GSK spotlights PhIII heart, cancer blockbuster hopefuls in late-stage R&D review. Article

> Merck ignores red flags and throws dice on PhII/III Alzheimer's gamble. News

Biotech IT News

> Stanford to rival Broad Institute with Big Data-focused genomics center. Report

> Study: Genomics, outsourcing fuel double-digit growth in bioinformatics. Article

> Social media, iPhone app aid efforts to crowdsource disease surveillance. News

> Why Big Data alone lacks the punch pharma needs. Story

CRO News

> Indian regulators want crackdown on unethical CROs. Report

> CROs lack oversight, report says; ACRO cries foul. Story

> AMRI shutters R&D site, moving jobs to Singapore. News

> Parexel partners with Taiwan hospital for drug development. More

And Finally... The American Psychiatric Association voted to approve its new diagnostic manual, which includes some controversial changes in autism and depression diagnoses. Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.